Diagnostic and therapeutic consensus on acromegaly

Journal of Endocrinological Investigation

Volumn 28, Issue 5 SUPPL, 2005, Pages 56-60

  Doga, M ^a   Bonadonna, S ^a   Gola, M ^a   Nuzzo, M ^a   Giustina, A ^a,b  

^a UNIVERSITY OF BRESCIA   (Italy)

^b SPEDALI CIVILI   (Italy)

Author keywords

Acromegaly; Diagnosis; IGF I; Oral glucose

Indexed keywords

DOPAMINE RECEPTOR STIMULATING AGENT; GROWTH HORMONE; GROWTH HORMONE RECEPTOR BLOCKING AGENT; HORMONE RECEPTOR BLOCKING AGENT; PEGVISOMANT; SOMATOMEDIN BINDING PROTEIN 3; SOMATOMEDIN C; SOMATOSTATIN DERIVATIVE; UNCLASSIFIED DRUG;

ACROMEGALY; CONFERENCE PAPER; CONSENSUS; GASTROINTESTINAL SYMPTOM; GLUCOSE BLOOD LEVEL; GROWTH HORMONE SECRETING ADENOMA; HEALTH CARE ORGANIZATION; HUMAN; MEDICAL PRACTICE; ORAL GLUCOSE TOLERANCE TEST; PRACTICE GUIDELINE; TREATMENT OUTCOME; TREATMENT PLANNING; UNSPECIFIED SIDE EFFECT; CONSENSUS DEVELOPMENT; ENDOCRINOLOGY;

ACROMEGALY; ENDOCRINOLOGY; HUMANS;

EID: 27744592832     PISSN: 03914097     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (32)

1. Melmed S. Acromegaly. N Engl J Med 1990, 322: 966-77.
2. Melmed S, Jackson I, Kleinberg D, Klibanski A. Current treatment guidelines for acromegaly. J Clin endocrinol Metab 1998, 83: 2646-52.
3. Frohman LA. Acromegaly: what constitutes optimal therapy? J Clin endocrinol Metab 1996, 81: 443-5.
4. Swearingen B, Barker FG, Kaznelson L, et al. Long-term mortality after transsphenoidal surgery and adjunctive therapy for acromegaly. J Clin Endocrinol Metab 1998, 83: 3419-26.
5. Abosch A, Tyrell JB, Lamborn KR, et al. Transsphenoidal microsurgery for growth hormone-secreting pituitary adenomas: initial outcome and long-term results. J Clin Endocrinol Metab 1998, 83: 3411-8.
6. Rajasoorya C, Holdaway IM, Wrightson P, Scott DJ, Ibbertson HK. Determinants of clinical outcome and survival in acromegaly. Clin Endocrinol (Oxf) 1994, 41: 95-102.
7. Bates AS, Van't Hoff W, Jones JM, Clayton RN. An audit of outcome of treatment in acromegaly. Q J Med 1993, 86: 293-9.
8. Giustina A, Barkan A, Casanueva FF, et al. Criteria for cure of acromegaly: a consensus statement. J Clin Endocrinol Metab 2000, 85: 526-9.
9. Giustina A, Casanueva FF, Cavagnini F, et al. Diagnosis and treatment of acromegaly complications. J Endocrinol Invest 2003, 26: 1242-7.
10. Chang-De Moranville BM, Powell JS, Wardlaw SL Diagnosis and endocrine testing in acromegaly. Endocrinol Metab Clin North Am 1992, 21: 649-68.
11. Ho KKy, Weissberger AJ. Characterization of 24 hour growth hormone secretion in acromegaly: implications for diagnosis and therapy. Clin Endocrinol (Oxf) 1994, 41: 75-83.
12. Freda PU, Post KD, Powel JS, Wardlaw SL. Evaluation of disease status with sensitive measures of GH secretion in 60 post-operative patients with acromegaly. J Clin Endocrinol Metab 1998, 83: 3808-16.
13. Trainer PJ. Editorial: acromegaly-consensus, what consensus? J Clin Endocrinol Metab 2002, 87: 3534-6.
14. Dimaraki EV, Jaffe CA, DeMott-Friberg R, Chandler WF, Barkan AL. Acromegaly with apparently normal GH secretion: implications for diagnosis and follow up. J Clin Endocrinol-Metab 2002, 87: 3537-42.
15. Jones JL, Clemmons DR. Insulin-like growth factors, and their binding proteins biological actions. Endocr Rev 1995, 16: 3-26.
16. Melmed S, Casanueva FF, Cavagnini F, et al. Guidelines for acromegaly management. J Clin Endocrinol Metab 2002, 87: 4054-8.
17. Tulipano G, Bonfanti C, Milani G, et al. Differential inhibition of growth hormone secretion by analogs selective for somatostatin receptors subtypes 2 and 5 in human growth-hormone-secreting adenoma cells in vitro. Neuroendocrinology 2001, 73: 344-51.
18. Cozzi R, Attanasio M, Montini M, et al. Four-year treatment with octreotide-long-acting repeatable in 110 acromegalic patients: predictive value of short term results? J Clin Endocrinol Metab 2003, 88: 3090-8.
19. Ambrosio MR, Franceschetti P, Bondanelli M, et al. Efficacy and safety of the new 60-mg formulation of the long-acting somatostatin analog lanreotide in the treatment of acromegali. Metabolism 2002, 51: 387-93.
20. A. Giustina, G. Zaltieri, F. Negrini, W.B. Wehrenberg. The Pharmacological aspects of the treatment of acromegaly. Pharmacol Res 1996, 34: 247-68.
21. Jaffe Ca, Barkan AL. Treatment of acromegaly with dopamine agonists. Endocrinol Metab Clin North Am 1992, 21: 713-35.
22. Caron P, Beckers A, Cullen DR, et al. Efficacy of the new long-acting formulation of lanreotide (lanreotide autogel) in the management of acromegaly. J Clin Endocrinol Metab 2002, 87: 99-104.
23. Gillis JC, Noble S, Goa KL. Octreotide long-acting release (LAR). A review of its pharmacological properties and therapeutic use in the management of acromegaly. Drugs 1997, 53: 681-99.
24. Abs R, Verhelst J, maiter D, et al. Cabergoline in the treatment of acromegaly: a study in 64 patients. J Clin Endocrinol Metab 1998, 83: 374-8.
25. Trainer PJ, Drake WM, Katznelson L, et al. Treatment of acromegaly with the growth -receptor antagonist pegvisomant. N Engl J Med 2000, 342: 1171-7.
26. Hermann-Bonert VS, Zib K, Scarlett JA, Melmed S. Growth hormone receptor antagonist therapy in acromegalic patients resistant to somatostatin analogs. J Clin Endocrinol Metab 2000, 85: 2958-61.
27. Landolt AM, Haller D, Lomax N, et al. Stereotactic radiosurgery for recurrent surgically treated acromegaly: comparison with fractionated radiotherapy. J Neurosurg 1998, 88: 1002-8.
28. Amato G, Mazziotti G, Rotondi M, et al. Long-term effects of lanreotide SR and octreotide LAR on tumor shrinkage and GH hypersecretion in patients with previously untreated acromegaly. Clin Endocrinol (Oxf) 2002, 56: 65-71.
29. Ciric I, Ragin A, Baumgartner C, Pierce D. Complications of transsphenoidal surgery: results of a national survey, review of the literature, and personal experience. Neurosurgery 1997, 40: 225-37.
30. Brada M, Ford D, Ashley S, et al. Risk of second brain tumor after conservative surgery and radiotherapy for pituitary adenoma. Br Med J 1992, 304: 1343-6.
31. Barkan AL, Halasz L, Dornfeld KJ, et al. Pituitary irradiation is ineffective in normalizing plasma insuline-like growth factor I in patients with acromegaly. J Clin Endocrinol Metab 1997, 82: 3187-91.
32. Ayuk J, Clayton RN, Holder G, Sheppard MC, Stewart PM, Bates SA. Growth hormone and pituitary radiotherapy, but not serum insulin-like growth factor-I concentrations, predict excess mortality in patients with acromegaly. J Clin Endocrinol Metab 2004, 89: 1613-7.